123 related articles for article (PubMed ID: 37188605)
1. Corrigendum to "The -172 A-to-G variation in ADAM17 gene promoter region affects EGR1/ADAM17 pathway and confers susceptibility to septic mortality with sepsis-3.0 criteria" [Int. Immunopharmacol. 102 (2022) 108385].
He J; Zhao T; Liu L; Liao S; Yang S; Lu F; Hong Y; Wei N; Cheng H; Zhang W; Shao Y
Int Immunopharmacol; 2023 Jun; 119():110285. PubMed ID: 37188605
[No Abstract] [Full Text] [Related]
2. The -172 A-to-G variation in ADAM17 gene promoter region affects EGR1/ADAM17 pathway and confers susceptibility to septic mortality with sepsis-3.0 criteria.
He J; Zhao T; Liu L; Liao S; Yang S; Lu F; Hong Y; Wei N; Cheng H; Zhang W; Shao Y
Int Immunopharmacol; 2022 Jan; 102():108385. PubMed ID: 34862128
[TBL] [Abstract][Full Text] [Related]
3. Retraction notice to "Corrigendum to "MLL1 promotes migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis by activating the TRIF/NF-κB signaling pathway via H3K4me3 enrichment in the TLR4 promoter region"" [Int. Immunopharmacol. 82 (2020) 106220] [Int. Immunopharmacol. 92 (2021) 107321].
Zhang Y; Ji T; Ma S; Wu W
Int Immunopharmacol; 2023 Apr; 117():109865. PubMed ID: 36822094
[No Abstract] [Full Text] [Related]
4. A Functional Polymorphism-Mediated Disruption of EGR1/ADAM10 Pathway Confers the Risk of Sepsis Progression.
Chen F; Wang Y; Zhang W; Cai Y; Zhao T; Mai H; Tao S; Wei W; Li J; Chen X; Li X; Tang P; Fan W; Yang J; Ou M; Lu F; Lai Z; Chen H; Zou T; Sun F; Shao Y; Cui L
mBio; 2019 Aug; 10(4):. PubMed ID: 31387910
[TBL] [Abstract][Full Text] [Related]
5. Association Study Between Promoter Polymorphisms of ADAM17 and Progression of Sepsis.
Shao Y; He J; Chen F; Cai Y; Zhao J; Lin Y; Yin Z; Tao H; Shao X; Huang P; Yin M; Zhang W; Liu Z; Cui L
Cell Physiol Biochem; 2016; 39(4):1247-61. PubMed ID: 27607600
[TBL] [Abstract][Full Text] [Related]
6. Corrigendum to "Sivelestat ameliorates sepsis-induced myocardial dysfunction by activating the PI3K/AKT/mTOR signaling pathway" [Int. Immunopharmacol. 128 (2024) https://doi.org/10.1016/j.intimp.2023.111466].
Geng H; Zhang H; Cheng L; Dong S
Int Immunopharmacol; 2024 Apr; 131():111873. PubMed ID: 38514302
[No Abstract] [Full Text] [Related]
7. Corrigendum to "Inhibition of MRP4 alleviates sepsis-induced acute lung injury in rats" [Int. Immunopharmacol. 72 (2019) 211-217].
Xia W; Zhang H; Pan Z; Li G; Zhou Q; Hu D; Liu Y
Int Immunopharmacol; 2023 Sep; 122():110699. PubMed ID: 37500384
[No Abstract] [Full Text] [Related]
8. Corrigendum to "MEGF6 prevents sepsis-induced acute lung injury in mice" [Int. Immunopharmacol. 123 (2023) 110727].
Liang H; Liu G; Zeng W; Fan Q; Nie Z; Hu H; Zhang R; Xie S
Int Immunopharmacol; 2024 May; 133():111787. PubMed ID: 38641473
[No Abstract] [Full Text] [Related]
9. Corrigendum to "Neutrophil elastase in dexmedetomidine alleviating sepsis-related renal injury in rats" [Int. Immunopharmacol. 122 (2023) 110441].
Chen L; Li M; Lin Y; Li Y; Liang M; Zeng K
Int Immunopharmacol; 2024 Feb; 128():111577. PubMed ID: 38281885
[No Abstract] [Full Text] [Related]
10. Corrigendum to "Gypenoside XLIX attenuates sepsis-induced splenic injury through inhibiting inflammation and oxidative stress" [Int. Immunopharmacol. 127 (2024) 111420].
Xu B; Yang R; Qiang J; Xu X; Zhou M; Ji X; Lu Y; Dong Z
Int Immunopharmacol; 2024 Apr; 131():111694. PubMed ID: 38368241
[No Abstract] [Full Text] [Related]
11. Corrigendum to "Maclurin inhibits caspase-11 non-canonical inflammasome in macrophages and ameliorates acute lethal sepsis in mice" [Int. Immunopharmacol. 129 (2024) 111615].
Lee DJ; Lee SY; Yi YS
Int Immunopharmacol; 2024 May; 132():111969. PubMed ID: 38575463
[No Abstract] [Full Text] [Related]
12. Corrigendum to "Curcumin attenuates sepsis-induced acute organ dysfunction by preventing inflammation and enhancing the suppressive function of Tregs" [Int. Immunopharmacol. 61 (2018) 1-7].
Chen L; Lu Y; Zhao L; Hu L; Qiu Q; Zhang Z; Li M; Hong G; Wu B; Zhao G; Lu Z
Int Immunopharmacol; 2024 Jun; ():112471. PubMed ID: 38879417
[No Abstract] [Full Text] [Related]
13. Genetic variants of ADAM17 are implicated in the pathological process of Kawasaki disease and secondary coronary artery lesions via the TGF-β/SMAD3 signaling pathway.
Peng Q; Deng Y; Yang X; Leng X; Yang Y; Liu H
Eur J Pediatr; 2016 May; 175(5):705-13. PubMed ID: 26833052
[TBL] [Abstract][Full Text] [Related]
14. Corrigendum to "(E)-2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl)phenol alleviates inflammatory responses in LPS-induced mice liver sepsis through inhibition of STAT3 phosphorylation" [Int. Immunopharmacol. 125(Part B) (2023) 111124].
Kim B; Yu JE; Yeo IJ; Son DJ; Lee HP; Roh YS; Lim KH; Yun J; Park H; Han SB; Hong JT
Int Immunopharmacol; 2024 Jun; ():112543. PubMed ID: 38926074
[No Abstract] [Full Text] [Related]
15. Ectodomain Shedding by ADAM17: Its Role in Neutrophil Recruitment and the Impairment of This Process during Sepsis.
Mishra HK; Ma J; Walcheck B
Front Cell Infect Microbiol; 2017; 7():138. PubMed ID: 28487846
[TBL] [Abstract][Full Text] [Related]
16. Corrigendum to "Emodin ameliorates ulcerative colitis by the flagellin-TLR5 dependent pathway in mice" [Int. Immunopharmacol. 59 (2018) 269-275].
Luo S; Deng X; Liu Q; Pan Z; Zhao Z; Zhou L; Luo X
Int Immunopharmacol; 2018 Sep; 62():337. PubMed ID: 29983242
[No Abstract] [Full Text] [Related]
17. Corrigendum to "Methyl helicterilate ameliorates alcohol-induced hepatic fibrosis by modulating TGF-β1/Smads pathway and mitochondria-dependent pathway" [Int. Immunopharmacol. 75 (2019) 105759].
Wen S; Wei Y; Zhang X; Bai F; Tan S; Nie J; Wei J; Lin X
Int Immunopharmacol; 2021 Mar; 92():107344. PubMed ID: 33418247
[No Abstract] [Full Text] [Related]
18. Corrigendum to "What is the impact and efficacy of routine immunological, biochemical and hematological biomarkers as predictors of COVID-19 mortality?" [Int. Immunopharmacol. 105 (2022) 108542].
Huyut MT; Huyut Z; Ilkbahar F; Mertoğlu C
Int Immunopharmacol; 2023 Oct; 123():110821. PubMed ID: 37625945
[No Abstract] [Full Text] [Related]
19. Corrigendum to "Gallic acid improved inflammation via NF-κB pathway in TNBS-induced ulcerative colitis" [Int. Immunopharmacol. 67 (2019) 129-137].
Zhu L; Gu P; Shen H
Int Immunopharmacol; 2021 Oct; 99():107815. PubMed ID: 34130920
[No Abstract] [Full Text] [Related]
20. Corrigendum to "Taxifolin ameliorates Benzo[a]pyrene-induced lung injury possibly via stimulating the Nrf2 signalling pathway" [Int. Immunopharmacol. 96 (2021) 107566].
Islam J; Shree A; Vafa A; Afzal SM; Sultana S
Int Immunopharmacol; 2023 Jun; 119():110096. PubMed ID: 37095029
[No Abstract] [Full Text] [Related]
[Next] [New Search]
